Search research articles
Contact Us
Filters
Showing results (121-130 of 125) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 125 results.
Cell
|
May 6, 1994
Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gamma 1 complexed with a high affinity binding peptide
S M Pascal, A U Singer, G Gish, et al.
Biochemistry
|
May 30, 1995
Solution structure of a cellulose-binding domain from Cellulomonas fimi by nuclear magnetic resonance spectroscopy
G Y Xu, E Ong, N R Gilkes, et al.
Biochemistry
|
May 17, 1994
Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation
N A Farrow, R Muhandiram, A U Singer, et al.
Leukemia
|
August 30, 2008
Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma
X Mao, X Li, R Sprangers, et al.
Cell Death & Disease
|
July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
Z Wang, P Dove, X Wang, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 125) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 125 results.
Cell
|
May 6, 1994
Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gamma 1 complexed with a high affinity binding peptide
S M Pascal, A U Singer, G Gish, et al.
Biochemistry
|
May 30, 1995
Solution structure of a cellulose-binding domain from Cellulomonas fimi by nuclear magnetic resonance spectroscopy
G Y Xu, E Ong, N R Gilkes, et al.
Biochemistry
|
May 17, 1994
Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation
N A Farrow, R Muhandiram, A U Singer, et al.
Leukemia
|
August 30, 2008
Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma
X Mao, X Li, R Sprangers, et al.
Cell Death & Disease
|
July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
Z Wang, P Dove, X Wang, et al.
Page
of 13